Lacouture, Mario

Publications

Sort by

Co-Author Network

selected publications

Drugs as a Frequent Cause of Acute Rash in Patients after CD34⁺-Selected Peripheral Blood Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Academic Article GET IT
Times cited: 3
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 134
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 165
Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Academic Article GET IT
Times cited: 5
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast cancer research and treatment. 2018 Review GET IT
Times cited: 20
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer discovery. 2018 Academic Article GET IT
Times cited: 98
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 218
Pruritus Associated with Targeted Anticancer Therapies and Their Management. Dermatologic clinics. 2018 Review GET IT
Times cited: 20
Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. 2018 GET IT
Times cited: 1
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA dermatology. 2018 Academic Article GET IT
Times cited: 51
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology. 2018 Academic Article GET IT
Times cited: 216
Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. Journal of the American Academy of Dermatology. 2017 Academic Article GET IT
Times cited: 21
Granuloma annulare associated with immune checkpoint inhibitors. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017 Letter GET IT
Times cited: 19
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 14
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. 2017 GET IT
Times cited: 66
Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. Acta dermato-venereologica. 2017 Academic Article GET IT
Times cited: 12
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 10
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 Academic Article GET IT
Times cited: 133
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 11
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016 Review GET IT
Times cited: 32
Dermatological adverse events with taxane chemotherapy. European journal of dermatology : EJD. 2016 Review GET IT
Times cited: 120
Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer. 2016 GET IT
Stoma care products represent a common and previously underreported source of peristomal contact dermatitis. Contact dermatitis. 2016 Academic Article GET IT
Times cited: 32
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 128
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. The oncologist. 2016 Review GET IT
Times cited: 102
Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. The oncologist. 2016 Review GET IT
Times cited: 50
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 44
Mechanisms of skin aging induced by EGFR inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2016 Academic Article GET IT
Times cited: 19
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 15
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 112
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer (Oxford, England : 1990). 2016 Review GET IT
Times cited: 287
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. 2016 GET IT
Times cited: 217
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016 Academic Article GET IT
Times cited: 8
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis. 2015 GET IT
Times cited: 7
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 313
Clinical and dermoscopic features of combined cutaneous squamous cell carcinoma (SCC)/neuroendocrine [Merkel cell] carcinoma (MCC). Journal of the American Academy of Dermatology. 2015 Academic Article GET IT
Times cited: 21
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
Alopecia in patients treated with molecularly targeted anticancer therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 38
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 966
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 245
The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. The British journal of dermatology. 2015 Letter GET IT
Times cited: 32
Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. The American Journal of dermatopathology. 2015 Academic Article GET IT
Times cited: 11
Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". Journal of the American Academy of Dermatology. 2015 Letter GET IT
Times cited: 1
Xerosis and pruritus as major EGFRI-associated adverse events. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 Academic Article GET IT
Times cited: 34
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 13
Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 84
Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clinical and experimental dermatology. 2015 Review GET IT
Times cited: 33
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 54
Management of dermatologic toxicities. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 7
Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatric blood & cancer. 2015 Academic Article GET IT
Times cited: 24
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 19
Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer investigation. 2015 Review GET IT
Times cited: 25
Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology. 2015 Review GET IT
Times cited: 31
Nasal vestibulitis due to targeted therapies in cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 Academic Article GET IT
Times cited: 18
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 213
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer immunology, immunotherapy : CII. 2015 Academic Article GET IT
Times cited: 94
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 Review GET IT
Times cited: 24
Differential radiation dermatitis in native skin and an autologous transplanted myocutaneous flap. 2014 GET IT
T-DM1-related telangiectasias: a potential role in secondary bleeding events. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Letter GET IT
Times cited: 10
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 105
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 20
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2014 Academic Article GET IT
Times cited: 16
Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor. JAMA dermatology. 2014 Academic Article GET IT
Times cited: 1
Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Review GET IT
Times cited: 112
Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2014 Review GET IT
Times cited: 25
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. 2014 GET IT
Times cited: 18
Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. Acta oncologica (Stockholm, Sweden). 2014 Review GET IT
Times cited: 9
Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. American journal of clinical oncology. 2014 Review GET IT
Times cited: 17
Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 20
EMPACT syndrome: limited evidence despite a high-risk cohort. Journal of neuro-oncology. 2014 Academic Article GET IT
Times cited: 3
Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology. 2014 Review GET IT
Times cited: 141
Dermoscopic findings in cutaneous metastases. JAMA dermatology. 2014 Academic Article GET IT
Times cited: 52
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. Journal of hepatology. 2014 Academic Article GET IT
Times cited: 62
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Seminars in oncology. 2014 Academic Article GET IT
Times cited: 70
Life-threatening dermatologic adverse events in oncology. Anti-cancer drugs. 2014 Academic Article GET IT
Times cited: 47
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. 2014 GET IT
Times cited: 34
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC cancer. 2014 Academic Article GET IT
Times cited: 5
Dermatologic infections in cancer patients. Cancer treatment and research. 2014 Review GET IT
Times cited: 11
Alopecia with endocrine therapies in patients with cancer. The oncologist. 2013 Academic Article GET IT
Times cited: 40
Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Current treatment options in oncology. 2013 Review GET IT
Times cited: 17
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2013 Review GET IT
Times cited: 72
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Review GET IT
Times cited: 172
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. American journal of clinical dermatology. 2013 Academic Article GET IT
Times cited: 108
Skin toxicity of targeted cancer agents: mechanisms and intervention. Future oncology (London, England). 2013 Review GET IT
Times cited: 21
Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Letter GET IT
Times cited: 11
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clinical lymphoma, myeloma & leukemia. 2013 Review GET IT
Times cited: 33
Dermatological adverse events from BRAF inhibitors: a growing problem. Current oncology reports. 2013 Review GET IT
Times cited: 38
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Investigational new drugs. 2013 Review GET IT
Times cited: 78
Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2013 Academic Article GET IT
Times cited: 5
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert review of anticancer therapy. 2013 Review GET IT
Times cited: 69
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 170
Skin necrosis induced by generic enoxaparin. American journal of hematology. 2013 Letter GET IT
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 111
Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Academic Article GET IT
Times cited: 14
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. European journal of haematology. 2013 Review GET IT
Times cited: 28
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology. 2013 Review GET IT
Times cited: 112
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investigational new drugs. 2013 Review GET IT
Times cited: 52
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatologic therapy. 2013 Review GET IT
Times cited: 37
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Academic Article GET IT
Times cited: 63
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Academic Article GET IT
Times cited: 32
Skin care for cancer patients. Clinical advances in hematology & oncology : H&O. 2012 Academic Article GET IT
Times cited: 1
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. Journal of drugs in dermatology : JDD. 2012 Academic Article GET IT
Times cited: 52
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast cancer research and treatment. 2012 Review GET IT
Times cited: 28
Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3. 2012 GET IT
Times cited: 12
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 197
Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 89
Anticancer therapy-induced adverse events: practicing damage control. Expert opinion on drug safety. 2012 Editorial Article GET IT
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. Journal of the American Academy of Dermatology. 2012 Academic Article GET IT
Times cited: 242
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012 Academic Article GET IT
Times cited: 27
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2012 Review GET IT
Times cited: 38
Characteristics of oral mucosal events related to bevacizumab treatment. 2012 GET IT
Times cited: 20
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 34
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. The oncologist. 2011 Review GET IT
Times cited: 79
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. European journal of cancer (Oxford, England : 1990). 2011 Review GET IT
Times cited: 42
Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Archives of dermatology. 2011 Academic Article GET IT
Times cited: 34
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology. 2011 Review GET IT
Times cited: 55
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Comment GET IT
Times cited: 50
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. The oncologist. 2011 Review GET IT
Times cited: 55
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clinical colorectal cancer. 2011 Academic Article GET IT
Times cited: 36
Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient. 2011 GET IT
Times cited: 9
The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. Journal of the American Academy of Dermatology. 2011 Review GET IT
Times cited: 71
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Current opinion in oncology. 2011 Review GET IT
Times cited: 36
Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clinical and experimental dermatology. 2011 Academic Article GET IT
Times cited: 15
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2011 Review GET IT
Times cited: 329
Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. 2011 GET IT
Times cited: 4
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 127
The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Review GET IT
Times cited: 25
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investigational new drugs. 2011 Review GET IT
Times cited: 45
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 25
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. International journal of dermatology. 2011 Review GET IT
Times cited: 50
Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia. 2011 GET IT
Times cited: 19
Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatologic therapy. 2011 Review GET IT
Times cited: 94
Cutaneous and mucosal reactions to oncologic therapy. Dermatologic therapy. 2011 Academic Article GET IT
Times cited: 4
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). 2010 GET IT
Times cited: 67
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 36
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer. 2010 Academic Article GET IT
Times cited: 140
Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. Journal of the American Academy of Dermatology. 2010 Letter GET IT
Times cited: 13
Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5. American journal of hematology. 2010 Letter GET IT
Times cited: 4
Skin care management in cancer patients: an evaluation of quality of life and tolerability. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010 Academic Article GET IT
Times cited: 32
Treatment of multiple keratoacanthomas with erlotinib. 2010 GET IT
Times cited: 9
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010 Academic Article GET IT
Times cited: 120
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 368
Dermatologic toxicities of targeted anticancer therapies. The journal of supportive oncology. 2010 Review GET IT
Times cited: 57
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clinical pharmacology and therapeutics. 2009 Academic Article GET IT
Times cited: 82
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Journal of the National Cancer Institute. 2009 Academic Article GET IT
Times cited: 136
Unanticipated toxicities from anticancer therapies: survivors' perspectives. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2009 Academic Article GET IT
Times cited: 54
Effect of sunitinib on renal cell carcinoma cutaneous metastasis. International journal of dermatology. 2009 Letter GET IT
Times cited: 5
Eosinophilic rash secondary to temsirolimus. 2009 GET IT
Times cited: 15
Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology. 2009 Review GET IT
Times cited: 58
Dermatologic issues in adult survivors of childhood cancer. Journal of cancer survivorship : research and practice. 2009 Academic Article GET IT
Times cited: 9
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2009 Review GET IT
Times cited: 102
Magnetic resonance imaging of paronychia induced by cetuximab. Clinical and experimental dermatology. 2009 Letter GET IT
Times cited: 4
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009 Academic Article GET IT
Times cited: 64
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). The oncologist. 2009 Review GET IT
Times cited: 90
The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park, N.Y.). 2009 Comment GET IT
Times cited: 19
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Current oncology (Toronto, Ont.). 2009 Academic Article GET IT
Times cited: 113
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clinical genitourinary cancer. 2009 Review GET IT
Times cited: 85
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. The journal of supportive oncology. 2009 Review GET IT
Times cited: 23
Blackberry-induced hand-foot skin reaction to sunitinib. 2008 GET IT
Times cited: 19
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. The oncologist. 2008 Review GET IT
Times cited: 285
Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clinical colorectal cancer. 2008 Review GET IT
Times cited: 14
The role of inhibitors of the epidermal growth factor in management of head and neck cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2008 Review GET IT
Times cited: 14
Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast cancer research and treatment. 2008 Review GET IT
Times cited: 73
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 212
An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical journal of oncology nursing. 2008 Conference Paper GET IT
Times cited: 58
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European journal of cancer (Oxford, England : 1990). 2008 Conference Paper GET IT
Times cited: 100
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2008 Review GET IT
Times cited: 97
Gadolinium-associated nephrogenic systemic fibrosis. Community oncology. 2008 Academic Article GET IT
Times cited: 1
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden). 2008 Review GET IT
Times cited: 167
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007 Academic Article GET IT
Times cited: 163
Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park, N.Y.). 2007 Review GET IT
Times cited: 15
Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park, N.Y.). 2007 Academic Article GET IT
Times cited: 26
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, N.Y.). 2007 Review GET IT
Times cited: 51
Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park, N.Y.). 2007 Academic Article GET IT
Times cited: 108
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Letter GET IT
Times cited: 5
p63 in Primary Cutaneous Carcinosarcoma. 2007 GET IT
Times cited: 22
The era of targeted therapies: increasing role for novel oncologic drugs in dermatology. Archives of dermatology. 2007 Editorial Article GET IT
Times cited: 1
Temporal dependence of the effect of radiation on erlotinib-induced skin rash. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Letter GET IT
Times cited: 24
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. The oncologist. 2007 Review GET IT
Times cited: 323
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. 2007 GET IT
Times cited: 47
Hand-foot and stump syndrome to sorafenib. 2007 GET IT
Times cited: 38
Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin therapy letter. 2007 Review GET IT
Times cited: 74
Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer nursing. 2007 Review GET IT
Times cited: 21
Non-rash skin toxicities associated with novel targeted therapies. Clinical lung cancer. 2006 Review GET IT
Times cited: 22
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. The Journal of molecular diagnostics : JMD. 2006 Academic Article GET IT
Times cited: 37
Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews. Cancer. 2006 Review GET IT
Times cited: 627
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. The British journal of dermatology. 2006 Letter GET IT
Times cited: 90
KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma. 2006 GET IT
Times cited: 25
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. 2006 GET IT
Times cited: 76
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. 2006 GET IT
Times cited: 77
Ossified soft tissue leiomyoma in a patient with sickle cell anemia. 2005 GET IT
Times cited: 10
The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. Journal of the American Academy of Dermatology. 2005 Review GET IT
Times cited: 48
Human papillomavirus-associated dysplastic condyloma of the tongue treated with Mohs micrographic surgery. 2005 GET IT
Times cited: 3
Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. 2005 GET IT
Times cited: 19
Skin rash in a transplant patient receiving multiple drugs. 2003 GET IT
Times cited: 2
A comparison of type I collagen, fibronectin, and vitronectin in supporting adhesion of mechanically strained osteoblasts. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2002 Academic Article GET IT
Times cited: 44
gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nature immunology. 2001 Academic Article GET IT
Times cited: 81

more ...

less ...

Background

education and training

M.D., Pontifical Javerian University, Faculty of Medicine (Colombia) 1997

Contact

full name

Mario Lacouture

VIVO Weill Cornell Medical College

Mario Lacouture Professor of Clinical Dermatology

Publications

selected publications

Background

education and training

Contact

full name